GE Healthcare: FDA approves Flyrcado (flurpiridaz F 18) radioactive diagnostic for enhanced diagnosis of coronary artery disease
GE HealthCare announced that the FDA has granted approval of Flyrcado (flurpiridaz F 18) injection, a first of its kind positron emission tomography myocardial perfusion imaging (PET MPI) agent, for the detection of coronary artery disease (CAD).
Read full article »
GE Healthcare is an Illinois-based multinational medical technology company that manufactures medical equipment and diagnostic products for healthcare organizations.
Read more